# Phibro Animal Health Corporation (PAHC) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Drug Manufacturers - Specialty & Generic. Price $37.65, market value $1.5 billion.

## Valuation
- **P/E (trailing): 15.5×** (5-yr avg 66.9×, 3-yr avg 101.5×). Phibro Animal Health Corporation trades at 15.5× trailing earnings, well below its own five-year average of 66.9×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 9.8×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.09**. A PEG of 0.09 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.0×**. Each dollar of revenue is priced at 1.0×.
- **Price / book: 4.0×**. The shares trade at 4.0× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 8.5×**. Enterprise value is 8.5× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 0.6%** (5-yr avg 0.7%). Free cash flow equals 0.6% of the market value, in line with its five-year average of 0.7%.
- **Earnings yield: 6.5%**. The inverse of the P/E: 6.5% of the price is earned each year.

## Profitability
- **Gross margin: 33.8%**. Phibro Animal Health Corporation keeps 33.8% of revenue after the direct cost of what it sells.
- **Operating margin: 12.8%**. 12.8% of revenue is left after running the business.
- **Net margin: 6.6%**. 6.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 25.9%**. 25.9% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 16.3%**. Return on all capital, debt included, is 16.3%: comfortably above what that capital costs.
- **Return on assets: 6.6%**. Each dollar of assets produces 6.6% of profit.

## Growth
- **Revenue growth (1 yr): 17.1%** (3-yr 15.8%/yr, 5-yr 12.7%/yr). Revenue grew 17.1% over the last year, against 12.7% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 104.2%** (3-yr 44.2%/yr, 5-yr 12.6%/yr). Earnings per share rose 104.2%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 1.60**. Debt is 1.60 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 2.3×**. It would take 2.3 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 2.96** (quick 2.96). Current assets cover the next year's liabilities 2.96 times.
- **Altman Z-score: 3.11**. A Z-score of 3.11 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend yield: 1.28%** ($0.48 per share, trailing). Phibro Animal Health Corporation yields 1.28%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 20%** (197% of free cash flow). 20% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 12**. 12 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 0.0%/yr** (1-yr 0.0%). The dividend has not grown over five years.

## Price and momentum
- **Total return (1 yr): -7.0%** (YTD 4.4%, 3-mo 4.3%). The shares are down 7.0% over twelve months including dividends.
- **From 52-week high: -37.3%** (33.3% above the low). Trading 37% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 56**. An RSI of 56 is neutral.
- **Beta (1 yr): 0.73** (volatility 54%). Beta of 0.73 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PAHC · Page: https://foliofundamentals.com/stocks/pahc

Not investment advice.